Histologically- or cytologically-confirmed CRC that is metastatic
Must have histologically confirmed advanced CRC that is metastatic.
KRAS Mutant CRC: Advanced KRAS mutant CRC who have progressed or are ineligible for both irinotecan and oxaliplatin based chemotherapy
KRAS Wild Type CRC: Advanced KRAS wild type CRC who have progressed or are ineligible for both irinotecan and oxaliplatin based chemotherapy and who are relapsed or refractory to at least  prior systemic therapy that included an anti-EGFR antibody, such as cetuximab, panitumumab or others.
Colorectal cancer (CRC) (not mismatch repair deficient by local assay including PCR and/or immunohistochemistry)
Any advanced solid tumor, with the exception of colorectal carcinoma (CRC), which is Microsatellite Instability (MSI)-High (MSI-H)
More than one prior line of systemic therapy for advanced CRC
Must have immune checkpoint nave histologically/cytologically confirmed advanced or metastatic CRC.
Colorectal carcinoma (CRC).
Histologically or cytologically-confirmed diagnosis of metastatic KRAS wildtype colorectal cancer (CRC)
Histologically- or cytologically- confirmed CRC
Metastatic CRC
Known or suspected high-frequency microsatellite instability (MSI-H) CRC
Histologically- or cytologically-confirmed CRC
Group : KRAS mutant CRC.(Part B)
Histologically-confirmed metastatic CRC
Phase  expansion: MSI high CRC
MSI status is, respectively, determined by examining CRC tumor.
For CRC:
For CRC, hemoglobin ?. g/dL
For CRC, prior treatment with cetuximab or panitumumab
Subjects with recurrent (unresectable) or metastatic CRC:
Have histologically confirmed microsatellite stable (MSS) CRC.
Histologically- or cytologically- confirmed CRC
Metastatic or recurrent CRC
Must not have received prior systemic chemotherapy for Stage IV CRC
Retinoblastoma-positive, histologically proven CRC with measurable disease
CRC: at least  prior systemic regimens in the metastatic setting, and as appropriate in patients whose tumors are microsatellite instability-high (MSI-H), pembrolizumab as well.
Histologically or cytologically confirmed diagnosis of CRC
Metastatic CRC not amenable to surgical resection
CRC (Colorectal cancer): Patients with metastatic CRC and known KRAS (Kirsten rat sarcoma viral oncogene homolog) status who are eligible for treatment with regorafenib in accordance with the approved labeling.
Have a history of Stage IV Colorectal Cancer (CRC) with metastases to the liver only
Have pathology-proven complete removal of all primary and liver metastatic CRC lesions. Subjects with positive margins will not be eligible for the study.
Patient must have histologically or cytologically confirmed refractory colorectal cancer (CRC)
Patients with solid tumor other than CRC.
Stage I-III colorectal cancer (CRC).
Patients who are at elevated risk for CRC, defined as having ever been diagnosed with CRC, a precancerous (adenomatous) polyp, or inflammatory bowel disease
No history of CRC
Individualswithpersonalhistoryofcolorectal cancer (CRC) or colorectal polyps
Be non-adherent to one or more recommended screenings for BC, CC, or CRC by Medical Record Review (MRR)
Individuals that fall within the age range for CRC screening surveillance from AHP
Are eligible for CRC screening surveillance from AHP
Are not eligible for CRC screening surveillance from AHP
Have a terminal medical illness that would otherwise categorize them as inappropriate candidates for CRC screening; these are: the individual must have any of the following noted in their EPIC electronic medical records (EMR): personal history of CRC, colectomy, colostomy, or ileostomy
FOLLOW-UP ASSESSMENTS: Must be non-adherent for CRC screening at the time of the educational program
Previous diagnosis of CRC
Up to date with CRC screening guidelines.
Family history of CRC diagnosed before the age of  years
Personal history of CRC
Pathologically or cytologically confirmed diagnosis of metastatic (stage IV) RAS wildtype CRC
Patients with a history of CRC without clear evidence of metastatic disease who have completed their acute cancer-specific treatment
Average-risk patients due for colorectal cancer (CRC) screening at the time of a primary care appointment who initiate a portal session within the two-week period following their visit
A personal history of CRC
Specific CRC risk factors, including:\r\n* First degree relative with CRC\r\n* Personal history of adenomatous polyps\r\n* Recent blood in stools\r\n* Currently taking medication for a diagnosis of dementia
Patients currently receiving active therapy for any cancer, including CRC or NSCLC